PŘEHLEDOVÉ ČLÁNKY Steatóza jater a diabetes mellitus 2. typu | 175 / Vnitř Lék. 2025;71(3):170-175 / VNITŘNÍ LÉKAŘSTVÍ www.casopisvnitrnilekarstvi.cz PROHLÁŠENÍ AUTORŮ: Prohlášení o původnosti: Práce je původní a nebyla publikována ani není zaslána k recenznímu řízení do jiného média. Střet zájmů: Žádný. Financování: Článek byl podpořen projektem RVO-VFN00064165 (Podpořeno MZ ČR – RVO VFN64165). Poděkování: N/A. Registrace v databázích: N/A. Projednání etickou komisí: N/A. LITERATURA 1. Ayonrinde OT. Historical narrative from fatty liver in the nineteenth century to contemporary NAFLD – Reconciling the present with the past. JHEP REPORT. 2021; 3, 3. Doi10.1016/j.jhepr.2021.100261. 2. Rinella ME, Neruschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the Clinical Assessment and Management of Nonalcoholic Fatty Liver Disease. Hepatology. 2023;77:1797-1835. 3. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966-1986. 4. Šmíd V, Dvořák K. Jaterní manifestace metabolického syndromu se nyní jmenuje MASLD – aktuální pohled na nejčastější onemocnění jater současnosti. Vnitř Lék. 2024;70(1):E8-E14. https://doi.org/10.36290/vnl.2024.013. 5. Cao L, An Y, Liu HY, et al. Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: a systematic review and meta‑analysis. BMC Medicine 2024; 22:101. doi.org/10.1186/ s12916-024-03315-0. 6. Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851-861. 7. Simon TG, Roelstraete B, Khalili H, et al. Mortality in Biopsy-Confrmed Nonalcoholic Fatty Liver Disease. Gut. 2021;70(7):1375-382. 8. Li Y, Yang P, Ye J, et al. Updated mechanisms of MASLD pathogenesis. Lipids in Health and Disease (2024) 23:117. doi.org/10.1186/s12944-024-02108-x 9. Dong T, Li J, Liu Y, et al. Roles of immune dysregulation in MASLD. Biomedicine & Pharmacotherapy 170 (2024) 116069. 10. Škrha J. Patogeneze diabetes mellitus 1. a 2. typu v roce 2011 – jednotící model poruchy glykoregulace. Vnitř Lék. 2011;57:949-953. 11. Ahlqvist E, Storm P, Karajamaki A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diab & Endocrinol. 2018;6:361-369. 12. Škrha J. Klasifikace diabetu 2022 – perspektiva moderního přístupu k diabetu. Acta medicinae. 2022;15:30-33. 13. Martinez-Sánchez FD, Medina-Julio D, Cordova-Gallardo J, et al. Type 2 Diabetes Subtypes and Their Role in Metabolic Liver Disease and Fibrosis Progression. Med Sci Monit. 2024;30:e946016. 14. Gurjar S, Bhat RA, Upadhya R, Shen RP. Extracellular vesicle-mediated approaches for the diagnosis and therapy of MASLD: current advances and future prospective. Lipids in Health and Disease. 2025; 24:5 doi.org/10.1186/s12944-024-02396-3. 15. Kim J, Ito T, Arai T, et al. Modified FIB-4 Index in Type 2 Diabetes Mellitus with Steatosis: A Non-Linear Predictive Model for Advanced Hepatic Fibrosis. Diagnostics. 2024;14:2500. doi.org/10.3390/diagnostics14222500. 16. Malandris K, Korakas E, Sarakapiona A, et al. Accuracy of Controlled Attenuation Parameter for Liver Steatosis in HighRisk Patients for MASLD Using MRIProton Density Fat Fraction as Reference Standard. Digestive Diseases and Sciences. 2024; doi.org/10.1007/ s10620-024-08799-7. 17. Korc M. Pancreatic Cancer-Associated Diabetes Is an „Exosomopathy“. Clin Cancer Res. 2015; 21:1508-1510. 18. Kumar J, Mohsin S, Hasan M, et al. Cardiovascular outcomes post bariatric surgery in patients with metabolic dysfunction-associated steatotic liver disease – A systematic review and meta-analysis. Clinics and Research in Hepatology and Gastroenterology. 2024; 48: 102261. 19. Soresi M, Giannitrapani L. Glucagon-like peptide 1 agonists are potentially useful drugs for treating metabolic dysfunction-associated steatotic liver disease. World J Gastroenterol. 2024;30(30):3541-3547. 20. Kuo CC, Chuang MH, Li CH, et al. Glucagon-Like Peptide-1 Receptor Agonists and Liver Outcomes in Patients With MASLD and Type 2 Diabetes. Alimentary Pharmacology & Therapeutics. 2025;0:1-12 doi.org/10.1111/apt.18502. 21. Ito D, Shimizu S, Haisa A, et al. Long-term effects of ipragliflozin and pioglitazone on metabolic dysfunctionassociated steatotic liver disease in patients with type 2 diabetes: 5 year observational follow-up of a randomized, 24 week, activecontrolled trial Effect of ipragliflozin in MASLD. J Diabetes Investig. 2024;15:1220-1230.
RkJQdWJsaXNoZXIy NDA4Mjc=